PGK1 and benign prostatic hyperplasia: Due to low numbers of patients being prescribed terazosin, mainly for benign prostatic hyperplasia, the “treated” groups have included those patients prescribed doxazosin or alfuzosin since they also contain the predicted PGK1-binding domain, whereas tamsulosin is used as an α1-adrenergic receptor antagonist structurally distinct from terazosin without a known PGK1 binding domain.